Results 81 to 90 of about 17,710 (254)

Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos, Line Kibsgaard, Trine Bertelsen   +2 more
wiley   +1 more source

Human and computational models of atopic dermatitis:A review and perspectives by an expert panel of the International Eczema Council [PDF]

, 2018
Atopic dermatitis (AD) is a prevalent disease worldwide and is associated with systemic comorbidities representing a significant burden on patients, their families, and society. Therapeutic options for AD remain limited, in part because of a lack of well-
Bieber, Thomas, Bissonette, Robert, Brown, Sara J., Dhar, Sandipan, Eyerich, Kilian, Guttman-Yassky, Emma, Hijnen, Dirk J., Irvine, Alan, Paller, Amy S., Perez White, Bethany E., Reynolds, Nick J., Tanaka, Reiko J., Thyssen, Jacob P., Vestergaard, Christian, Werfel, Thomas, Wollenberg, Andreas   +15 more
core   +5 more sources

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son   +11 more
wiley   +1 more source

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran, Meier, Katharina, Solimani, Farzan   +2 more
core   +1 more source

Successful Treatment of Severe Adult Linear IgA Dermatosis Using Dupilumab

JEADV Clinical Practice, EarlyView.
ABSTRACT Linear IgA dermatosis (LAD) is a rare autoimmune subepidermal bullous dermatosis, characterised by the presence of erythematous vesiculobullous lesions arranged in rosettes or herpetiform clusters. The standard treatment involves the administration of dapsone, followed by sulfasalazine, and general corticosteroid therapy, often in combination ...
Célia Delesalle, Claire Abasq‐Thomas, Claire Bocciarelli, Amélie Bourhis, Marina Alexandre, Belen Eguia, Laurent Misery, Numa Deydier   +7 more
wiley   +1 more source

Facial erythema after the treatment of dupilumab in SLE patient

Allergy, Asthma & Clinical Immunology, 2020
Background Dupilumab is a receptor antagonist binding to the alpha subunit of the interleukin-4 receptor. Through binding to it, dupilumab inhibits signaling of both IL-4 and IL-13, the representative Th2 biomarkers.
Dong Hyek Jang, Jae In Lee, Joo Yoon Bae, Hye Jung Jung, Mi Yeon Park, Jiyoung Ahn   +5 more
doaj   +1 more source

Cytokine and Lipid Mediator Regulation of Group 2 Innate Lymphoid Cells (ILC2s) in Human Allergic Airway Disease. [PDF]

, 2017
The recent discovery of group 2 innate lymphoid cells (ILC2s) has caused a paradigm shift in the understanding of allergic airway disease pathogenesis.
Cavagnero, Kellen, Doherty, Taylor A
core   +2 more sources

REVEAL AD ‐ Prevalence of Moderate and Severe Atopic Dermatitis in Ireland: A Cross‐ Sectional, Real World Study of a Secondary Care Population

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a common inflammatory skin disease. However, limited data exist on its prevalence and incidence in Irish secondary care. Objectives REVEAL AD had two distinct but related objectives: (1) Estimate prevalence of moderate‐to‐severe AD in patients aged 12 years and older presenting to secondary care clinics in ...
Oisín S. Gough, Fiona McEvoy, Moneeb Saddiq, Michael O'Connell, Maeve Lynch, Brian Kirby, Michelle Murphy   +6 more
wiley   +1 more source

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events

Journal for ImmunoTherapy of Cancer
Background Dupilumab has been added to National Cancer Comprehensive Network guidelines as a therapeutic strategy for managing certain cutaneous immune-related adverse events (cirAEs) from immune checkpoint blockade (ICB).
Shadmehr Demehri, Kerry L Reynolds, Yevgeniy R Semenov, Matthew Tran, Nicole R LeBoeuf, Suzanne Xu, Guihong Wan, Bonnie W Leung, Emma Beagles, Sara Khattab, Cameron Moseley, Chuck Lin, Marjan Azin, Ninghui Hao   +13 more
doaj   +1 more source

The Role of Artificial Intelligence in Modern Allergology: A Review of Applications in Diagnosis, Prediction, and Management

JEADV Clinical Practice, EarlyView.
ABSTRACT Artificial Intelligence is rapidly transforming allergology by enhancing diagnosis, risk prediction, automation, patient communication, education, and therapy development. Machine learning approaches, including convolutional neural networks, recurrent architectures, and transformer‐based models, enable analysis of complex datasets from ...
Sebastian Seurig, Stephan Traidl, Sonja Mathes   +2 more
wiley   +1 more source